Search

Background: Abrocitinib, an oral Janus kinase 1 inhibitor, provided significant itch relief by week 2 in patients with moderate-to-severe atopic dermatitis (AD) in the phase III JADE COMPARE trial. Objectives: This post-hoc analysis of JADE COMPARE aimed to further characterize itch response and determined whether early itch relief could predict subsequent improvements in AD severity. Methods: JADE COMPARE was a randomized, double-blind, double-dummy, placebo-controlled trial. Adult patients (aged ≥ 18 years) with moderate-to-severe AD were randomly assigned to receive oral abrocitinib 200 mg or 100 mg once daily, subcutaneous dupilumab 300 mg every other week (after a 600-mg loading dose), or placebo, plus medicated topical therapy for 16 weeks. Assessments were ≥ 4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) from days 2 to 15, Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA) response, and Dermatology Life Quality Index (DLQI) scores at week 12. Association between week 2 PP-NRS4 and efficacy at week 12 was evaluated by chi-squared tests. The predictive value of early response for later efficacy was assessed by area under the receiver operating characteristic curve. Results: As early as day 4 after treatment, a significantly greater proportion of patients achieved PP-NRS4 response with abrocitinib 200 mg (18.6%) versus dupilumab (5.6%; p

When prescribing low-dose methotrexate, frequent serological testing is recommended in the dermatologic literature, although much of the supporting data is extrapolated from non-dermatologic conditions. We performed a retrospective cohort study to determine the cumulative incidence and timing of low-dose methotrexate-associated serological abnormalities over the first year of therapy, in a pragmatic cohort of patients with dermatologic compared to non-dermatologic diagnoses. Laboratory values recorded included white blood cell count, hemoglobin, platelet count, estimated glomerular filtration rate, alanine aminotransferase, and aspartate aminotransferase. Among 1376 patients, there were no cases of methotrexate-associated grade 4/very severe lab abnormality or fatality. Baseline risk factors associated with moderate-to-severe lab abnormalities included non-dermatologic diagnoses, low hemoglobin, low estimated glomerular filtration rate, and elevated transaminases. The incidence of moderate-to-severe lab abnormalities was 4.4% among all patients, 3.1% among patients with dermatologic diagnoses, and 2.3% among patients with normal baseline lab values. Lab abnormalities led to discontinuation of therapy in 0.8% of patients. Serious changes did not occur in the first two weeks of therapy. We conclude that the cumulative incidence of low-dose methotrexate-associated lab abnormality was lower in patients with dermatologic diagnoses or normal baseline testing and these factors may be used to adjust monitoring practices.

Atopic dermatitis is a common, chronic inflammatory dermatosis that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this final section, treatments for flare prevention and adjunctive and complementary therapies and approaches are reviewed. Suggestions on use are given based on available evidence.

Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in atopic dermatitis management and care, providing recommendations based on the available evidence. In this third of 4 sections, treatment of atopic dermatitis with phototherapy and systemic immunomodulators, antimicrobials, and antihistamines is reviewed, including indications for use and the risk-benefit profile of each treatment option.

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and2% to 3% of adults. This guideline addresses important clinical questions that arise in the managementand care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed.Known risk factors for the development of disease are also reviewed.

Modern Field-Programmable Gate Arrays (FPGAs) can accommodate complex system-on-chip designs and require extensive intellectual-property (IP) support. However, current IP protection mechanisms in FPGAs are limited, and do not reach beyond whole-design bitstream encryption. This work presents an architecture and protocol for securing IP based designs in programmable platforms. The architecture is reprsented by the Secure Authentication Module (SAM), an enabler for next-generation intellectual-property exchange in complex FPGAs. SAM protects hardware, software, application data, and also provides mutual assurances for the end-user and the intellectual-property developer. Further, this work demonstrates the use of SAM in a secure video messaging device on top of a Virtex-II Pro development system. Master of Science

The Eczema Area and Severity Index (EASI); clinician-reported signs severity scale. (DOCX 15 kb)

The Patient Oriented Eczema Measure (POEM); patient-reported symptoms severity scale. (DOCX 1521 kb)

Diagnostic criteria (UK Working Party Diagnostic Criteria for Atopic Dermatitis). (DOCX 11 kb)

The Patient Oriented Eczema Measure (POEM); patient-reported symptoms severity scale. (DOCX 1521 kb)

Checklist: recommended items to address in a clinical trial protocol and related documents*. (DOC 121 kb)

Diagnostic criteria (UK Working Party Diagnostic Criteria for Atopic Dermatitis). (DOCX 11 kb)

Checklist: recommended items to address in a clinical trial protocol and related documents*. (DOC 121 kb)

The Eczema Area and Severity Index (EASI); clinician-reported signs severity scale. (DOCX 15 kb)